1 / 18

Pertussis and Pertussis Vaccines

Pertussis and Pertussis Vaccines. Epidemiology and Prevention of Vaccine-Preventable Diseases National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention. Revised May 2009. Pertussis Clinical Features. Catarrhal stage 1-2 weeks

boucherc
Télécharger la présentation

Pertussis and Pertussis Vaccines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pertussis and Pertussis Vaccines Epidemiology and Prevention of Vaccine-Preventable Diseases National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Revised May 2009

  2. Pertussis Clinical Features • Catarrhal stage 1-2 weeks • Paroxysmalcough stage 1-6 weeks • Convalescence Weeks to months

  3. Pertussis Among Adolescents and Adults • Disease often milder than in infants and children • Infection may be asymptomatic, or may present as classic pertussis • Persons with mild disease may transmit the infection • Older persons often source of infection for children

  4. Pertussis Complications* Condition Pneumonia SeizuresEncephalopathy Hospitalization Death Percent reported 4.9 0.7 0.1 16 0.2 *Cases reported to CDC 2001-2003 (N=28,998)

  5. Pertussis Complications by Age *Cases reported to CDC 1997-2000 (N=28,187)

  6. Pertussis—United States, 1980-2007 Year

  7. Reported Pertussis by Age Group, 1990-2007

  8. Pertussis-containing Vaccines • DTaP (pediatric) • approved for children 6 weeks through 6 years (to age 7 years) • Tdap (adolescent and adult) • approved for persons 10 through 64 years (Boostrix) and 11 through 64 years (Adacel)

  9. DTaP Clinical Trials VE (95% CI) 85% (80-89) 80% (59-90) 84% (76-89) Product Daptacel Tripedia Infanrix Location Sweden Germany Italy

  10. Routine DTaP Primary Vaccination Schedule Minimum Interval --- 4 wks 4 wks 6 mos Dose Primary 1 Primary 2 Primary 3 Primary 4 Age 2 months 4 months 6 months 15-18 months

  11. Pertussis Vaccine Use in Children with Underlying Neurologic Disorders Underlying Condition Prior seizure Suspected neurologic disorder Neurologic event between doses Stable/resolved neurologic condition Recommendation Delay and assess* Delay and assess* Delay and assess* Vaccinate *vaccinate after treatment initiated and condition stabilized

  12. DTaP Adverse Reactions • Local reactions 20%-40% (pain, redness, swelling) • Temp of 101oF 3%-5% or higher • More severe adverse reactions not common • Local reactions more common following 4th and 5th doses

  13. Adverse Reactions Following the 4th and 5th DTaP Dose • Local adverse reactions and fever increased with 4th and 5th doses of DTaP • Reports of swelling of entire limb • Extensive swelling after 4th dose NOT a contraindication to 5th dose

  14. DTaP Contraindications • Severe allergic reaction to vaccine component or following a prior dose • Encephalopathy not due to another identifiable cause occurring within 7 days after vaccination

  15. DTaP Precautions* • Moderate or severe acute illness • Temperature >105°F (40.5°C) or higher within 48 hours with no other identifiable cause • Collapse or shock-like state (hypotonic hyporesponsive episode) within 48 hours • Persistent, inconsolable crying lasting >3 hours, occurring within 48 hours • Convulsions with or without fever occurring within 3 days *may consider use in outbreaks

  16. Pertussis Among Adolescentsand Adults • Prolonged cough (3 months or longer) • Post-tussive vomiting • Multiple medical visits and extensive medical evaluations • Complications • Hospitalization • Medical costs • Missed school and work • Impact on public health system

  17. Recommendations for Tdap Vaccination of Adolescents • Adolescents 11 or 12 years of age should receive a single dose of Tdap instead of Td* • Adolescents 13 through 18 years who have not received Tdap should receive a single dose of Tdap as their catch-up booster instead of Td* *if the person has completed the recommended childhood DTaP/DTP vaccination series, and has not yet received a Td booster MMWR 2006;55(RR-3):1-43.

  18. Tdap Vaccination of Adults19 Through 64 Years of Age • Single dose of Tdap to replace a single dose of Td • May be given at an interval less than 10 years since receipt of last tetanus toxoid-containing vaccine • Special emphasis on adults with close contact with infants (e.g., childcare and healthcare personnel, and parents) MMWR 2006;55(RR-17):1-37.

More Related